256 related articles for article (PubMed ID: 36257537)
21. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
23. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
24. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario J; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin J; Choi J; Santin AD
Ann Oncol; 2021 Aug; 32(8):1045-1046. PubMed ID: 33932502
[No Abstract] [Full Text] [Related]
25. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
26. [Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer].
Raynaud C; Rodrigues M
Bull Cancer; 2024 May; 111(5):433-434. PubMed ID: 38493028
[No Abstract] [Full Text] [Related]
27. Endometrial carcinosarcoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Caruso G; Enomoto T; Takehara K; Denys H; Lorusso D; Coleman R; Vaughan MM; Takano M; Provencher DM; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Kim JW; Candido Dos Reis FJ; Ramirez PT; Mariani A; Leitao M; Makker V; Abu-Rustum NR; Vergote I; Zannoni G; Tan D; McCormack M; Paolini B; Bini M; Raspagliesi F; Benedetti Panici P; Di Donato V; Muzii L; Colombo N; Pignata S; Scambia G; Monk BJ
Int J Gynecol Cancer; 2023 Feb; 33(2):147-174. PubMed ID: 36585027
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma.
Turinetto M; Lombardo V; Pisano C; Musacchio L; Pignata S
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1039-1047. PubMed ID: 36111897
[TBL] [Abstract][Full Text] [Related]
29. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
30. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Rubinstein M; Shen S; Monk BJ; Tan DSP; Nogueira-Rodrigues A; Aoki D; Sehouli J; Makker V
Gynecol Oncol; 2022 Dec; 167(3):540-546. PubMed ID: 36280455
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy in oncogynaecology].
Nay P; Morice P; Blanc-Durand F
Bull Cancer; 2023 Apr; 110(4):395-401. PubMed ID: 36759214
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
Johnson RL; Ganesan S; Thangavelu A; Theophilou G; de Jong D; Hutson R; Nugent D; Broadhead T; Laios A; Cummings M; Orsi NM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760602
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
Gadducci A; Cosio S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
[TBL] [Abstract][Full Text] [Related]
34. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Bogani G; Monk BJ; Powell MA; Westin SN; Slomovitz B; Moore KN; Eskander RN; Raspagliesi F; Barretina-Ginesta MP; Colombo N; Mirza MR
Ann Oncol; 2024 May; 35(5):414-428. PubMed ID: 38431043
[TBL] [Abstract][Full Text] [Related]
35. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
37. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
[TBL] [Abstract][Full Text] [Related]
38. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
39.
Seban RD; Donnadieu A; Journo G; Bidard FC; Richard C; Rouzier R; Champion L
Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441288
[TBL] [Abstract][Full Text] [Related]
40. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.
Richardson M; Chase DM
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):1-8. PubMed ID: 37792525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
